199 related articles for article (PubMed ID: 30338648)
1. Influence of total glucosides of paeony on PD-1/PD-L1 expression in primary Sjögren's syndrome.
Chen Y; Wang Y; Xu L; Zhu W; Xu C; Xu M; Guo L; Hu W; Xu D; Jing R; Zhu Y; He J; Xu B
Int J Rheum Dis; 2019 Feb; 22(2):200-206. PubMed ID: 30338648
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immunological consequences of total glucosides of paeony treatment in Sjögren's syndrome: A randomized controlled pilot trial.
Zhou Y; Jin L; Kong F; Zhang H; Fang X; Chen Z; Wang G; Li X; Li X
Int Immunopharmacol; 2016 Oct; 39():314-319. PubMed ID: 27517517
[TBL] [Abstract][Full Text] [Related]
3. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
Luo L; Shu M; Li S; Cai Y
Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
[TBL] [Abstract][Full Text] [Related]
4. CD4+CXCR5+ follicular helper T cells in salivary gland promote B cells maturation in patients with primary Sjogren's syndrome.
Jin L; Yu D; Li X; Yu N; Li X; Wang Y; Wang Y
Int J Clin Exp Pathol; 2014; 7(5):1988-96. PubMed ID: 24966908
[TBL] [Abstract][Full Text] [Related]
5. IL-17-producing double-negative T cells are expanded in the peripheral blood, infiltrate the salivary gland and are partially resistant to corticosteroid therapy in patients with Sjögren's syndrome.
Alunno A; Bistoni O; Bartoloni Bocci E; Caterbi S; Bigerna B; Pucciarini A; Tabarrini A; Mannucci R; Beghelli D; Falini B; Gerli R
Reumatismo; 2013 Oct; 65(4):192-8. PubMed ID: 24192564
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of total glucosides of paeony in treating primary Sjögren's syndrome: a propensity-matched study.
Cui YY; Abdukiyum M; Xu XF; Zhang YQ; Zhao N; Jia ZY; Zheng YY; Jin ZY; Huang SS; Feng XB
Eur Rev Med Pharmacol Sci; 2024 May; 28(10):3523-3531. PubMed ID: 38856127
[TBL] [Abstract][Full Text] [Related]
7. [Clinical observation on effect of total glucosides of paeony in treating patients with non-systemic involved Sjögren syndrome].
Zhang HF; Hou P; Xiao WG
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Jul; 27(7):596-8. PubMed ID: 17717915
[TBL] [Abstract][Full Text] [Related]
8. Association of BAFF and IL-17A with subphenotypes of primary Sjögren's syndrome.
Deng F; Chen J; Zheng J; Chen Y; Huang R; Yin J; Gao X; Lin Q; Huang C; Gao Y; Yu X; Liu Z
Int J Rheum Dis; 2016 Jul; 19(7):715-20. PubMed ID: 25941062
[TBL] [Abstract][Full Text] [Related]
9. Percentages of PD-1
Wang Y; Pang N; Wang X; Liu Y; Wang X; Wang L; Sun M; Yasen H; Zhao F; Fan W; Guo X; Ding J
Hum Vaccin Immunother; 2018 Apr; 14(4):832-838. PubMed ID: 29333980
[TBL] [Abstract][Full Text] [Related]
10. Effects of total glucosides of paeony for delaying onset of Sjogren's syndrome: an animal study.
Li CL; He J; Li ZG; Zheng LW; Hua H
J Craniomaxillofac Surg; 2013 Oct; 41(7):610-5. PubMed ID: 23333492
[TBL] [Abstract][Full Text] [Related]
11. [Expressions and clinical significance of OX40 and OX40L in peripheral blood of patients with primary Sjogren's syndrome].
Zhu R; Jiang J; Wang T; Xu T; Wu M; Liu C; Zhang X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Aug; 29(8):862-5. PubMed ID: 23948416
[TBL] [Abstract][Full Text] [Related]
12. Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study.
Alunno A; Carubbi F; Bistoni O; Caterbi S; Bartoloni E; Di Benedetto P; Cipriani P; Giacomelli R; Gerli R
Clin Exp Immunol; 2016 Jun; 184(3):284-92. PubMed ID: 26814615
[TBL] [Abstract][Full Text] [Related]
13. The expression of P2X7 receptors on peripheral blood mononuclear cells in patients with primary Sjögren's syndrome and its correlation with anxiety and depression.
Xie B; Chen Y; Zhang S; Wu X; Zhang Z; Peng Y; Huang X
Clin Exp Rheumatol; 2014; 32(3):354-60. PubMed ID: 24480517
[TBL] [Abstract][Full Text] [Related]
14. [Expression of CD4+ CD25+ regulatory T cells in peripheral blood and salivary gland of patients with primary Sjögren's syndrome].
Li XM; Li XP; Qian L; Wang GS; Zhang H; Zhei ZM; Li Q; Chen K; Wang XQ; Wang YP
Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(15):1034-6. PubMed ID: 17672966
[TBL] [Abstract][Full Text] [Related]
15. Activity of T-helper cells in patients with primary Sjogren's syndrome.
Sudzius G; Mieliauskaite D; Butrimiene I; Siaurys A; Mackiewicz Z; Dumalakiene I
In Vivo; 2013; 27(2):263-8. PubMed ID: 23422488
[TBL] [Abstract][Full Text] [Related]
16. B cell subsets and dysfunction of regulatory B cells in IgG4-related diseases and primary Sjögren's syndrome: the similarities and differences.
Lin W; Jin L; Chen H; Wu Q; Fei Y; Zheng W; Wang Q; Li P; Li Y; Zhang W; Zhao Y; Zeng X; Zhang F
Arthritis Res Ther; 2014 May; 16(3):R118. PubMed ID: 24887143
[TBL] [Abstract][Full Text] [Related]
17. Total glucosides of paeony alleviates experimental Sjögren's syndrome through inhibiting NLRP3 inflammasome activation of submandibular gland cells.
Jiang T; Guo J; Wang Y; Wu H; Chen Y; Wang S; Zhang H; Long Q; Yao G
Clin Exp Rheumatol; 2023 Dec; 41(12):2502-2510. PubMed ID: 38149512
[TBL] [Abstract][Full Text] [Related]
18. SLAMF3 promotes Th17 differentiation and is reversed by iguratimod through JAK1/STAT3 pathway in primary Sjögren's syndrome.
Hu P; Cai J; Yang C; Xu L; Ma S; Song H; Yang P
Int Immunopharmacol; 2024 Jan; 126():111282. PubMed ID: 38061117
[TBL] [Abstract][Full Text] [Related]
19. Peripheral regulatory cells immunophenotyping in primary Sjögren's syndrome: a cross-sectional study.
Furuzawa-Carballeda J; Hernández-Molina G; Lima G; Rivera-Vicencio Y; Férez-Blando K; Llorente L
Arthritis Res Ther; 2013; 15(3):R68. PubMed ID: 23800367
[TBL] [Abstract][Full Text] [Related]
20. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome.
Lavie F; Miceli-Richard C; Ittah M; Sellam J; Gottenberg JE; Mariette X
Scand J Immunol; 2008 Feb; 67(2):185-92. PubMed ID: 18201372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
